Literature DB >> 17516657

Anti-oxidant constituents of the roots and stolons of licorice (Glycyrrhiza glabra).

Young-Won Chin1, Hyun-Ah Jung, Yue Liu, Bao-Ning Su, John A Castoro, William J Keller, Michael A Pereira, A Douglas Kinghorn.   

Abstract

As part of a search for new cancer chemopreventive agents, a new chalcone derivative (1), a novel group of neolignan lipid esters (2), and seven known phenolic compounds (formononetin, glabridin, hemileiocarpin, hispaglabridin B, isoliquiritigenin, 4'-O-methylglabridin, and paratocarpin B) (3-9) were isolated from the roots and stolons of licorice (Glycyrrhiza glabra). The structures of compound 1 and the individual components of isolate 2 were elucidated using various spectroscopic and chemical methods. All isolates were tested in an authentic peroxynitrite anti-oxidant assay. Of these compounds, hispaglabridin B (6), isoliquiritigenin (7), and paratocarpin B (9) were found to be the most potent anti-oxidant agents. Furthermore, isoliquiritigenin (7) was demonstrated to prevent the incidence of 1,2-dimethylhydrazine-induced colon and lung tumors in mice when administered at a dose of 300 mg/kg.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17516657     DOI: 10.1021/jf0703553

Source DB:  PubMed          Journal:  J Agric Food Chem        ISSN: 0021-8561            Impact factor:   5.279


  30 in total

1.  Isoliquiritigenin induces apoptosis and inhibits xenograft tumor growth of human lung cancer cells by targeting both wild type and L858R/T790M mutant EGFR.

Authors:  Sung Keun Jung; Mee-Hyun Lee; Do Young Lim; Jong Eun Kim; Puja Singh; Sung-Young Lee; Chul-Ho Jeong; Tae-Gyu Lim; Hanyong Chen; Young-In Chi; Joydeb Kumar Kundu; Nam Hyouck Lee; Charles C Lee; Yong-Yeon Cho; Ann M Bode; Ki Won Lee; Zigang Dong
Journal:  J Biol Chem       Date:  2014-11-03       Impact factor: 5.157

Review 2.  Natural products as aromatase inhibitors.

Authors:  Marcy J Balunas; Bin Su; Robert W Brueggemeier; A Douglas Kinghorn
Journal:  Anticancer Agents Med Chem       Date:  2008-08       Impact factor: 2.505

3.  Dietary chalcones with chemopreventive and chemotherapeutic potential.

Authors:  Barbora Orlikova; Deniz Tasdemir; Frantisek Golais; Mario Dicato; Marc Diederich
Journal:  Genes Nutr       Date:  2011-02-04       Impact factor: 5.523

4.  Protective effect of isoliquiritigenin against cerebral injury in septic mice via attenuation of NF-κB.

Authors:  Peng Zou; Hong-Ming Ji; Jian-Wei Zhao; Xin-Min Ding; Zi-Gang Zhen; Xuan Zhang; Xiao-Qi Nie; Li-Xiong Xue
Journal:  Inflammopharmacology       Date:  2018-06-26       Impact factor: 4.473

5.  Inhibitory effect of DNA topoisomerase inhibitor isoliquiritigenin on the growth of glioma cells.

Authors:  Shupeng Zhao; Haigang Chang; Pengju Ma; Guojun Gao; Cailing Jin; Xinli Zhao; Wenke Zhou; Baozhe Jin
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

6.  Glabridin, a bioactive component of licorice, ameliorates diabetic nephropathy by regulating ferroptosis and the VEGF/Akt/ERK pathways.

Authors:  Hongtao Tan; Junxian Chen; Yicong Li; Yingshan Li; Yunchang Zhong; Guangzhao Li; Lingling Liu; Yiqun Li
Journal:  Mol Med       Date:  2022-05-20       Impact factor: 6.376

7.  Isoliquiritigenin, a chalcone compound, enhances spontaneous inhibitory postsynaptic response.

Authors:  Junsung Woo; Suengmok Cho; C Justin Lee
Journal:  Exp Neurobiol       Date:  2014-06-13       Impact factor: 3.261

8.  Modulation of Estrogen Chemical Carcinogenesis by Botanical Supplements used for Postmenopausal Women's Health.

Authors:  Courtney S Snelten; Birgit Dietz; Judy L Bolton
Journal:  Drug Discov Today Dis Mech       Date:  2012-06-01

9.  Glycyrrhizic acid nanoparticles inhibit LPS-induced inflammatory mediators in 264.7 mouse macrophages compared with unprocessed glycyrrhizic acid.

Authors:  Wei Wang; Meng Luo; Yujie Fu; Song Wang; Thomas Efferth; Yuangang Zu
Journal:  Int J Nanomedicine       Date:  2013-04-12

10.  An update on antitumor activity of naturally occurring chalcones.

Authors:  En-Hui Zhang; Ru-Feng Wang; Shu-Zhen Guo; Bin Liu
Journal:  Evid Based Complement Alternat Med       Date:  2013-04-17       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.